Action TRML TOURMALINE BIO, INC.
Ajouter à une liste
Pour utiliser cette fonction vous devez être client ou membre
ConnexionInscription

Autres langues Tourmaline Bio, Inc.

Actions

TRML

US89157D1054

Marché Fermé - Nasdaq
Autres places de cotation
 22:00:00 11/06/2024 		Varia. 5j. Varia. 1 janv.
15,62 USD +2,76 % Graphique intraday de Tourmaline Bio, Inc. +15,28 % -40,34 %
16/05 Tourmaline Bio, Inc. lance le développement clinique de TOUR006 pour les maladies cardiovasculaires avec l'administration de la dose au premier patient de l'étude de phase 2 TRANQUILITY CI
13/05 Tourmaline Bio, Inc. annonce ses résultats pour le premier trimestre clos le 31 mars 2024 CI

Autres langues

Recherche
Voir les résultats
Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !
Inscription 100% Gratuite
Tourmaline Bio to Present at the Jefferies Global Healthcare Conference
Tourmaline Bio Initiates Clinical Development of TOUR006 for Cardiovascular Diseases with First Patient Dosed in Phase 2 TRANQUILITY Trial
Tourmaline Bio, Inc Initiates Clinical Development of TOUR006 for Cardiovascular Diseases with First Patient Dosed in Phase 2 TRANQUILITY Trial
Tourmaline Bio Reports First Quarter 2024 Financial Results and Recent Business Highlights
Tourmaline Bio, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
Certain Restricted Stock Units of Tourmaline Bio, Inc. are subject to a Lock-Up Agreement Ending on 25-APR-2024.
Certain Options of Tourmaline Bio, Inc. are subject to a Lock-Up Agreement Ending on 25-APR-2024.
Certain Common Stock of Tourmaline Bio, Inc. are subject to a Lock-Up Agreement Ending on 25-APR-2024.
Wall Street Set to Open Higher After Fed Holds Interest Rates Steady; Initial Jobless Claims Lower Than Expected
US Futures Trend Higher After Fed Decision to Hold Interest Rates Steady
Top Premarket Decliners
Tourmaline Reports Q4 Net Loss; Cash to Fund Operations Until 2027
Tourmaline Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights
Tourmaline Bio, Inc. Plans to Commence a Phase 2 Trial Evaluating Quarterly Subcutaneous Dosing of TOUR006 in Patients with Elevated Cardiovascular Risk in the First Half of 2024
Tourmaline Bio, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
Tourmaline Bio, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023
Tourmaline Bio Insider Bought Shares Worth $3,250,000, According to a Recent SEC Filing
Tourmaline Bio Announces Closing of $172.5 Million Public Offering of Common Stock, Including Full Exercise of the Underwriters’ Option to Purchase Additional Shares
Tourmaline Bio Prices $150 Million Common Stock Offering
Tourmaline Bio Announces Pricing of Public Offering of Common Stock
Aucun résultat pour cette recherche
Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Filtres

Rechercher

Date de publication

Depuis le

Jusqu'au

  1. Bourse
  2. Actions
  3. Action TRML
  4. Actualités Tourmaline Bio, Inc.
  5. Autres langues